Genmab A/S (NASDAQ:GMAB) Posts Earnings Results

Genmab A/S (NASDAQ:GMAB) announced its earnings results on Thursday. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.37 by $0.12, FiscalAI reports. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.11 billion. Genmab A/S had a return on equity of 15.34% and a net margin of 21.05%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab raised its 2026 guidance, now expecting revenue of DKK 4.3–4.5 billion and operating profit of DKK 1.1–1.4 billion. Revenue growth at the midpoint is projected at 19%, while operating expenses rise only 2%, highlighting expected operating leverage.
• First-half proprietary-product sales increased 37% to DKK 396 million, led by EPKINLY sales growth of 48% to DKK 312 million. Management cited accelerating U.S. community adoption, broader site activation, and strong uptake of the second-line follicular lymphoma regimen.
• Genmab reported statistically significant, clinically meaningful progression-free-survival results from the phase III EPCORE DLBCL-2 study and received European approval for EPKINLY plus lenalidomide and rituximab in second-line follicular lymphoma.
• Petosemtamab is being expanded into two global phase III colorectal cancer trials—frontline and second-line—in combination with chemotherapy. Management also expects frontline head-and-neck data in the fourth quarter and is positioning the asset as a potential multi-indication growth driver.
• Several major catalysts are expected in the coming quarters, including Rina-S phase II and III ovarian-cancer data and frontline EPKINLY data in the fourth quarter, while petosemtamab’s second- or third-line head-and-neck readout is now expected in the first quarter of 2027. Overall-survival data for the EPKINLY DLBCL study remain immature, and outcomes for these late-stage programs are still subject to clinical and regulatory uncertainty.

Genmab A/S Stock Performance

NASDAQ:GMAB traded up $0.57 during mid-day trading on Thursday, hitting $29.83. 5,232,595 shares of the stock were exchanged, compared to its average volume of 1,988,784. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S has a fifty-two week low of $21.00 and a fifty-two week high of $35.43. The firm’s 50-day simple moving average is $27.22 and its 200 day simple moving average is $27.99. The stock has a market capitalization of $18.60 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.84 and a beta of 0.83.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GMAB shares. Weiss Ratings raised Genmab A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, July 28th. New Street Research set a $43.00 target price on shares of Genmab A/S in a report on Wednesday, July 22nd. Truist Financial began coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd. Finally, TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and raised their price objective for the company from $32.00 to $43.00 in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.28.

Institutional Trading of Genmab A/S

Several large investors have recently bought and sold shares of the business. CIBC Private Wealth Group LLC grew its position in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 616 shares during the last quarter. NewEdge Advisors LLC boosted its stake in shares of Genmab A/S by 1,229.0% in the 3rd quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after purchasing an additional 1,143 shares in the last quarter. Brown Brothers Harriman & Co. grew its position in Genmab A/S by 143.4% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after acquiring an additional 780 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the period. Finally, Advisory Services Network LLC acquired a new position in shares of Genmab A/S in the 3rd quarter worth approximately $54,000. 7.07% of the stock is owned by institutional investors and hedge funds.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.